- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00651183
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Amstetten, Austria
- Boehringer Ingelheim Investigational Site
-
Bad Hall, Austria
- Boehringer Ingelheim Investigational Site
-
Bad Ischl, Austria
- Boehringer Ingelheim Investigational Site
-
Bad Radkersburg, Austria
- Boehringer Ingelheim Investigational Site
-
Baden, Austria
- Boehringer Ingelheim Investigational Site
-
Bregenz, Austria
- Boehringer Ingelheim Investigational Site
-
Bruck an der Mur, Austria
- Boehringer Ingelheim Investigational Site
-
Deutschlandsberg, Austria
- Boehringer Ingelheim Investigational Site
-
Dornbirn, Austria
- Boehringer Ingelheim Investigational Site
-
Eisenstadt, Austria
- Boehringer Ingelheim Investigational Site
-
Feldkirch, Austria
- Boehringer Ingelheim Investigational Site
-
Feldkirchen, Austria
- Boehringer Ingelheim Investigational Site
-
Gmunden, Austria
- Boehringer Ingelheim Investigational Site
-
Graz, Austria
- Boehringer Ingelheim Investigational Site
-
Grieskirchen, Austria
- Boehringer Ingelheim Investigational Site
-
Gänserndorf, Austria
- Boehringer Ingelheim Investigational Site
-
Hall in Tirol, Austria
- Boehringer Ingelheim Investigational Site
-
Hallein, Austria
- Boehringer Ingelheim Investigational Site
-
Hermagor, Austria
- Boehringer Ingelheim Investigational Site
-
Hohenems, Austria
- Boehringer Ingelheim Investigational Site
-
Hollabrunn, Austria
- Boehringer Ingelheim Investigational Site
-
Horn, Austria
- Boehringer Ingelheim Investigational Site
-
Imst, Austria
- Boehringer Ingelheim Investigational Site
-
Innsbruck, Austria
- Boehringer Ingelheim Investigational Site
-
Judenburg, Austria
- Boehringer Ingelheim Investigational Site
-
Kapfenberg, Austria
- Boehringer Ingelheim Investigational Site
-
Klagenfurt, Austria
- Boehringer Ingelheim Investigational Site
-
Klosterneuburg, Austria
- Boehringer Ingelheim Investigational Site
-
Knittelfeld, Austria
- Boehringer Ingelheim Investigational Site
-
Krems, Austria
- Boehringer Ingelheim Investigational Site
-
Kufstein, Austria
- Boehringer Ingelheim Investigational Site
-
Leoben, Austria
- Boehringer Ingelheim Investigational Site
-
Lienz, Austria
- Boehringer Ingelheim Investigational Site
-
Lilienfeld, Austria
- Boehringer Ingelheim Investigational Site
-
Linz, Austria
- Boehringer Ingelheim Investigational Site
-
Melk, Austria
- Boehringer Ingelheim Investigational Site
-
Neunkirchen, Austria
- Boehringer Ingelheim Investigational Site
-
Oberwart, Austria
- Boehringer Ingelheim Investigational Site
-
Ried im Innkreis, Austria
- Boehringer Ingelheim Investigational Site
-
Salzburg, Austria
- Boehringer Ingelheim Investigational Site
-
Scheibbs, Austria
- Boehringer Ingelheim Investigational Site
-
Schwechat, Austria
- Boehringer Ingelheim Investigational Site
-
Spital an der Drau, Austria
- Boehringer Ingelheim Investigational Site
-
St. Johann im Pongau, Austria
- Boehringer Ingelheim Investigational Site
-
St. Pölten, Austria
- Boehringer Ingelheim Investigational Site
-
St. Veit an der Glan, Austria
- Boehringer Ingelheim Investigational Site
-
Stegersbach, Austria
- Boehringer Ingelheim Investigational Site
-
Stockerau, Austria
- Boehringer Ingelheim Investigational Site
-
Telfs, Austria
- Boehringer Ingelheim Investigational Site
-
Traun, Austria
- Boehringer Ingelheim Investigational Site
-
Villach, Austria
- Boehringer Ingelheim Investigational Site
-
Vöcklabruck, Austria
- Boehringer Ingelheim Investigational Site
-
W. Neustadt, Austria
- Boehringer Ingelheim Investigational Site
-
Wels, Austria
- Boehringer Ingelheim Investigational Site
-
Wien, Austria
- Boehringer Ingelheim Investigational Site
-
Wolfsberg, Austria
- Boehringer Ingelheim Investigational Site
-
Wörgl, Austria
- Boehringer Ingelheim Investigational Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Idiopathic PD with or without fluctuations
- Indication for treatment with Pramipexole
- Presence of at least mild depressive symptoms (as judged by the treating physician)
- Ability to reliably complete a self-rating scale (Hospital Anxiety and Depression Scale (HADS))
Exclusion Criteria:
- Any contraindications according to the Summary of Product Characteristics (SPC), hypersensitivity to pramipexole or to any of the excipients
- Ongoing treatment with pramipexole
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behaviour and Mood)
Ramy czasowe: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Rating scale scored from 0 (none) - 4 (severe). The UPDRS Part I (Mentation, Behaviour and Mood during the Past Week) consist of 4 items, each of them is scored from 0 (normal) to 4 (severe). Reduction in this score over time is interpreted as improvement. Total UPDRS part I score ranges from 0 = best score to 16 = worst score |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-D Depression Subscore
Ramy czasowe: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Depression Scale - 7 items scored for each individual question from 0 = best and 3 = worst. HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale. |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-A Anxiety Subscore
Ramy czasowe: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Anxiety Scale - 7 items scored for each individual question from 0 = best and 3 = worst. HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale. |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in UPDRS Part III (Motor Examination)
Ramy czasowe: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
14 components rating scale with 27 items scored by 0 (none) - 4 (severe)
|
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Objawy behawioralne
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Zaburzenia Parkinsona
- Choroby jąder podstawy
- Zaburzenia ruchowe
- Synukleinopatie
- Choroby neurodegeneracyjne
- Depresja
- Choroba Parkinsona
- Fizjologiczne skutki leków
- Agentów neuroprzekaźników
- Molekularne mechanizmy działania farmakologicznego
- Środki ochronne
- Agoniści dopaminy
- Agentów dopaminy
- Przeciwutleniacze
- Agenci przeciw parkinsonowi
- Agenci przeciwko Dyskinezie
- Pramipeksol
Inne numery identyfikacyjne badania
- 248.649
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .